253 related articles for article (PubMed ID: 22815123)
1. Radionuclide therapy beyond radioiodine.
Gabriel M
Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
[TBL] [Abstract][Full Text] [Related]
2. [Nuclear medicine in oncotherapy].
Pávics L; Besenyi Z
Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
[TBL] [Abstract][Full Text] [Related]
3. [Radionuclide therapy for cancer--what's new?].
Hanna M; Mikko T
Duodecim; 2012; 128(21):2209-16. PubMed ID: 23210283
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
5. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
Parus JL; Mikolajczak R
Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
[TBL] [Abstract][Full Text] [Related]
6. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
7. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Flux G; Bardies M; Chiesa C; Monsieurs M; Savolainen S; Strand SE; Lassmann M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1699-700. PubMed ID: 17565497
[No Abstract] [Full Text] [Related]
8. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Bardiès M; Buvat I
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
[No Abstract] [Full Text] [Related]
9. Therapeutic nuclear medicine in pediatric malignancy.
Schmidt M; Baum RP; Simon T; Howman-Giles R
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):411-28. PubMed ID: 20823809
[TBL] [Abstract][Full Text] [Related]
10. Use of
Oliván-Sasot P; Falgás-Lacueva M; García-Sánchez J; Vera-Pinto V; Olivas-Arroyo C; Bello-Arques P
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):116-119. PubMed ID: 27793633
[TBL] [Abstract][Full Text] [Related]
11. Peptide receptor imaging and therapy.
Kwekkeboom D; Krenning EP; de Jong M
J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic advances of nuclear medicine in oncology].
Valdés Olmos RA; Hoefnagel CA; Bais E; Boot H; Taal B; de Kraker J; Vote PA
Rev Esp Med Nucl; 2001 Dec; 20(7):547-57. PubMed ID: 11709141
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry.
Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Krause BJ; Schümichen C; Bengel FM; Knapp WH; Bartenstein P; Biersack HJ; Plöckinger U; Schwartz-Fuchs S; Baum RP
Recent Results Cancer Res; 2013; 194():457-65. PubMed ID: 22918775
[TBL] [Abstract][Full Text] [Related]
15. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
Jadvar H
AJR Am J Roentgenol; 2017 Aug; 209(2):277-288. PubMed ID: 28463538
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
17. Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
Dillehay GL; Ellerbroek NA; Balon H; Brill DR; Grigsby PW; Macklis RM; Mauch PM; Mian TA; Potters L; Silberstein EB; Williams TR; Wong JC; Gaspar LE;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1299-307. PubMed ID: 16472933
[No Abstract] [Full Text] [Related]
18. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
[No Abstract] [Full Text] [Related]
19. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]